Updated core competencies in pharmacoepidemiology to inform contemporary curricula and training for academia, government, and industry.
competencies
curriculum
pharmacoepidemiology
training
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
revised:
07
03
2024
received:
15
11
2023
accepted:
22
03
2024
medline:
17
4
2024
pubmed:
17
4
2024
entrez:
17
4
2024
Statut:
ppublish
Résumé
The first paper to specify the core content of pharmacoepidemiology as a profession was published by an ISPE (International Society for Pharmacoepidemiology) workgroup in 2012 (Jones JK et al. PDS 2012; 21[7]:677-689). Due to the broader and evolving scope of pharmacoepidemiology, ISPE considers it important to proactively identify, update and expand the list of core competencies to inform curricula of education programs; thus, better positioning pharmacoepidemiologists across academic, government (including regulatory), and industry positions. The aim of this project was to update the list of core competencies in pharmacoepidemiology. To ensure applicability of findings to multiple areas, a working group was established consisting of ISPE members with positions in academia, industry, government, and other settings. All competencies outlined by Jones et al. were extracted from the initial manuscript and presented to the working group for review. Expert-based judgments were collated and used to identify consensus. It was noted that some competencies could contribute to multiple groups and could be directly or indirectly related to a group. Five core domains were proposed: (1) Epidemiology, (2) Clinical Pharmacology, (3) Regulatory Science, (4) Statistics and data science, and (5) Communication and other professional skills. In total, 55 individual competencies were proposed, of which 25 were new competencies. No competencies from the original work were dropped but aggregation or amendments were made where considered necessary. While many core competencies in pharmacoepidemiology have remained the same over the past 10 years, there have also been several updates to reflect new and emerging concepts in the field.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e5789Subventions
Organisme : International Society for Pharmacoepidemiology
Informations de copyright
© 2024 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.
Références
Edlavitch SA, Tilson HH. For consideration by pharmacoepidemiologists. Pharmacoepidemiol Drug Saf. 2021 Dec;30(12):1619‐1620. doi:10.1002/pds.5365
Beckmann J, Hagemann U, Bahri P, et al. Teaching pharmacovigilance: the WHO‐ISoP core elements of a comprehensive modular curriculum. Drug Saf. 2014;37(10):743‐759. doi:10.1007/s40264‐014‐0216‐1
Nwokeji ED, Rascati KL, Moczygemba LR, Wilson JP. Pharmacoepidemiology education in US colleges and schools of pharmacy. Am J Pharm Educ. 2007;71(4):80.
Jones JK, Tilson HH, Lewis JD. Pharmacoepidemiology: defining the field and its core content. Pharmacoepidemiol Drug Saf. 2012;21(7):677‐689. doi:10.1002/pds.3198
Stockklausner C, Lampert A, Hoffmann GF, Ries M. Novel treatments for rare cancers: the U.S. orphan drug act is delivering‐a cross‐sectional analysis. Oncologist. 2016;21(4):487‐493. doi:10.1634/theoncologist.2015‐0397
Radcliffe C, Palacios CF, Azar MM, Cohen E, Malinis M. Real‐world experience with available, outpatient COVID‐19 therapies in solid organ transplant recipients during the omicron surge. Am J Transplant. 2022;22(10):2458‐2463. doi:10.1111/ajt.17098
Goedecke T, Morales DR, Pacurariu A, Kurz X. Measuring the impact of medicines regulatory interventions‐systematic review and methodological considerations. Br J Clin Pharmacol. 2018;84(3):419‐433. doi:10.1111/bcp.13469
Pratt NL, Mack CD, Meyer AM, et al. Data linkage in pharmacoepidemiology: a call for rigorous evaluation and reporting. Pharmacoepidemiol Drug Saf. 2020;29(1):9‐17. doi:10.1002/pds.4924
Rivera DR, Gokhale MN, Reynolds MW, et al. Linking electronic health data in pharmacoepidemiology: appropriateness and feasibility. Pharmacoepidemiol Drug Saf. 2020;29(1):18‐29. doi:10.1002/pds.4918
Bourke A, Dixon WG, Roddam A, et al. Incorporating patient generated health data into pharmacoepidemiological research. Pharmacoepidemiol Drug Saf. 2020;29(12):1540‐1549. doi:10.1002/pds.5169
Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA. Trial designs using real‐world data: the changing landscape of the regulatory approval process. Pharmacoepidemiol Drug Saf. 2020;29(10):1201‐1212. doi:10.1002/pds.4932
Burcu M, Dreyer NA, Franklin JM, et al. Real‐world evidence to support regulatory decision‐making for medicines: considerations for external control arms. Pharmacoepidemiol Drug Saf. 2020;29(10):1228‐1235. doi:10.1002/pds.4975
The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology (Revision 10); Chapter 15.6. EMA/95098/2010.
McMillan SS, King M, Tully MP. How to use the nominal group and Delphi techniques. Int J Clin Pharm. 2016;38(3):655‐662. doi:10.1007/s11096‐016‐0257‐x